Press "Enter" to skip to content

Novel CAR T-Cell Therapy Promising in Mantle Cell Lymphoma

At December’s American Society of Hematology (ASH) virtual meeting, some results from the TRANSCEND-NHL-001 study were presented, which evaluated the efficacy and safety of a novel CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), in relapsed/refractory mantle cell lymphoma patients.

In this video courtesy of VJHemOnc, study co-author Michael Wang, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses these initial findings from the ongoing trial.

Following is a transcript of his remarks:

The TRANSCEND study is by BMS and Juno and Company and it has several cohorts. As we all know, the large cell lymphoma cohort part has been published in [The Lancet], and the FDA is looking at the data, and it is pending FDA approval, we hope very soon.

At ASH 2020, we reported the TRANSCEND mantle cell lymphoma part … [for patients who relapsed]. In this study population, we have 32 patients so far enrolled and ready for a preliminary data report, and they have a median prior therapies of over three, and so far the grade three or four toxicities for CRS [cytokine release syndrome] and neurotoxicity are very low and the overall response rate is 84% and the CR [complete response] is 66%, and this is indeed a very good set of data balancing the CRs and the low rate of CRS and neurotoxicity with a high response rate and especially the CR rate of 66%.

As we know, in the ZUMA-2 clinical trial that I led and published, the overall response rate is 93% and the CR rate is 67%.

So in the Juno clinical trial, the CR rate is as high as 66% and as such, a low cost of CRS and neurotoxicity. So, this is a very promising therapeutic modality and we are actively enrolling to finish this cohort so that we could make this therapy available to patients as soon as we could, and there are also differences with prior studies on mantle cell lymphoma, in that the infusion of CD4 and CD8 is at a one-per-one ratio, but a CD4 cell infusion and a CD8 cell infusion is consecutive.

In other words, they are infused separately, one after another in all the patients, and also the cells infused are between 50 million, 100 million, and 150 million for the large cell lymphoma cohort but for mantle cell lymphoma, the main cohort is 100 million cells.

As you can see there’s a dramatic difference between this one and the ZUMA-2 study that infused two million cells per kilogram, instead of 100 million. I would like to remind everybody, that the costimulation molecule is 4-1BB instead of ZUMA-2, with CD28. I cannot compare it with two clinical trials, but this set of data puts each other headed in the right context.

  • Greg Laub joined MedPage Today in 2005 as Production Manager and led the launch of the video department in 2007. He is currently responsible for the website’s video production. Follow